QBS-10072S is under clinical development by Quadriga BioSciences and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QBS-10072S’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QBS-10072S overview

QBS-10072S is under development for the treatment of solid tumors including bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer, triple negative breast cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, malignant pleural mesothelioma, prostate cancer, sarcoma, tongue cancer, thymic carcinoma, urinary tract cancer, brain tumor like glioblastoma multiforme, multiple myleoma and  brain metastases of breast cancers (metastatic breast cancer). The drug candidates constitute cytotoxic moiety chemically fused to a LAT1 specific recognition element. The drug candidate acts by targeting large amino acid transporter 1 (LAT1). It is administered through intravenous route.

Quadriga BioSciences overview

Quadriga BioSciences is an oncology start-up focused on developing targeted anti-cancer drugs. Quadriga BioSciences is headquartered in Los Altos, California, the US.

For a complete picture of QBS-10072S’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 January 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.